Malouff Timothy D, Seneviratne Danushka S, Ebner Daniel K, Stross William C, Waddle Mark R, Trifiletti Daniel M, Krishnan Sunil
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States.
Warren Alpert Medical School, Brown University, Providence, RI, United States.
Front Oncol. 2021 Feb 26;11:601820. doi: 10.3389/fonc.2021.601820. eCollection 2021.
Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget's disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.
硼中子俘获疗法（BNCT）是一种新兴的治疗方式，旨在提高传统上难以治疗的肿瘤的治疗比。BNCT利用含硼剂将硼-10优先递送至肿瘤，硼-10在接受中子照射后，产生锂-7和一个α粒子。α粒子射程短，因此优先影响肿瘤组织，同时 sparing 更多远端正常组织。迄今为止，BNCT已在多种疾病部位进行了临床研究，包括多形性胶质母细胞瘤、脑膜瘤、头颈癌、肺癌、乳腺癌、肝细胞癌、肉瘤、皮肤恶性肿瘤、乳腺外佩吉特病、复发性癌症、儿童癌症和转移性疾病。我们旨在对这些疾病部位的每项研究提供最新且全面的综述，以及对BNCT应用面临的挑战进行综述。
